Shots: Shots:

• Gilead has signed non-exclusive voluntary licensing agreements with Cipla- Ferozsons- Hetero- Jubilant Lifesciences and Mylan to manufacture remdesivir for distribution in 127 countries
• Gilead will share its manufacturing know-how with the five companies to ramp up remdesivir production with each company will be allowed to set the price for its generic version of the drug
• The licensees will not pay royalties to Gilead until the WHO declares the end of the Public Health Emergency of International Concern regarding COVID-19- or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat COVID-19

Click here to­ read full press release/ article 

Ref: Gilead | Image: Gilead

Related News: Gilead’s Veklury (remdesivir) Receives MHLW’s Approval for Patients with Severe COVID-19 in Japan